Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

In This Issue   |    
In This Issue
Am J Psychiatry 2007;164:A36-A36. doi:10.1176/appi.ajp.2007.164.9.A36
text A A A

Two clinically important findings from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) appear this month. Miklowitz et al. (p. 1340) found that intensive psychosocial intervention improves functioning in patients with bipolar depression. Compared to brief collaborative care, 30 sessions of cognitive behavior therapy, family-focused therapy, or interpersonal and social rhythm therapy produced greater improvements in relationships and life satisfaction, but not work/role performance or recreation. Goldberg et al. (CME, p. 1348) report that adjunctive antidepressant treatment does not improve the likelihood of recovery from bipolar depression with concomitant manic symptoms. Adding an antidepressant to a mood stabilizer for 145 patients resulted in recovery times similar to those for patients not taking an antidepressant, along with more severe manic symptoms at 3 months. Dr. Stephen Strakowski addresses the challenge of treating bipolar depression in an editorial on p. 1301.

Suicides by children and adolescents increased as antidepressant prescriptions for them decreased after public health warnings in 2003–2004 about possible suicidality in pediatric patients taking selective serotonin reuptake inhibitor antidepressants (SSRIs). Gibbons et al. (p. 1356) demonstrate this inverse relationship in both the United States and the Netherlands. Melhem et al. (p. 1364) identified several precursors of suicidal behavior in the offspring of parents with mood disorders. The offspring began the study at an average age of 20 years old. During the 6-year follow-up, suicide attempts or serious suicidal thoughts were more common among offspring with a mood disorder or impulsive aggression and among those with a parent who had attempted suicide, had been sexually abused, or was depressed. Dr. James Leckman and Dr. Robert King provide a developmental perspective in an editorial on p. 1304.

Lack of response to antidepressant treatment in depressed patients with a recent heart attack may signify a high risk of more cardiac events. De Jonge et al. (CME, p. 1371) assessed 70 patients treated for depression after suffering a myocardial infarction. Over 18 months, major heart problems occurred in 26% of the patients whose depression did not respond but only 7% of the responders. Otte et al. (p. 1379) report a possible genetic connection between heart disease and depression. The 5-HTTLPR polymorphism is part of a gene that influences intercellular serotonin transport. Among 557 cardiac patients, those with one or two copies of the 5-HTTLPR short allele had more depression, perceived stress, and urinary norepinephrine excretion than patients with two long alleles. Norepinephrine excretion is believed to reflect activity of the sympathetic nervous system, a possible link between heart disease and depression. Drs. Robert Carney and Kenneth Freedland discuss depression in cardiac patients in an editorial on p. 1307.


Aripiprazole in Schizophrenia

Hyperprolactinemia caused by antipsychotic drugs may respond to the addition of aripiprazole, an antipsychotic with a distinct pharmacological profile. Shim et al. (p. 1304) added aripiprazole to the haloperidol treatment of 26 patients with schizophrenia. Hyperprolactinemia was alleviated in 85%, compared to 4% for placebo. This normalization may be due to aripiprazole’s high affinity for dopamine D2 receptors. Using positron emission tomography, Mamo et al. (p. 1411) measured aripiprazole’s binding to D2 receptors. Therapeutic doses bound to more than 80% of available D2 receptors in the striatum of patients with schizophrenia or schizoaffective disorder. For most other antipsychotics, occupancy is 60%–65%. The threshold for producing extrapyramidal side effects was 90% for aripiprazole, compared to 80% for other antipsychotics. The clinical pharmacology of aripiprazole is discussed by Dr. Robert Kessler in an editorial on p. 1310.




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 12.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 45.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles
[Medication associated long QT syndrome]. Praxis (Bern 1994) 2009;98(24):1409-15; quiz 1415.